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Uncontrolled delayed nausea and vomiting remains a problem after high-dose preparative regimens used for
autologous and allogeneic hematopoietic stem cell transplants. Recently, aprepitant was approved for highly
and moderately emetogenic chemotherapy, and, in particular, is effective for decreasing delayed emesis. To
evaluate its safety and efﬁcacy in the transplantation setting, we performed a randomized, placebo-
controlled, phase 3 trial of aprepitant in combination with ondansetron and dexamethasone in patients
treated with ablative preparative regimens. Patients were randomized to receive oral aprepitant or placebo
daily with oral ondansetron and dexamethasone during and for 3 days after the completion of the preparative
regimen in this prospective randomized, double-blind study. The primary objective was complete response
(CR) rate, deﬁned as no emesis with no or mild nausea. Other endpoints included number of emetic episodes,
nausea severity assessed using a 100-mm visual analog scale (VAS), the need for rescue antiemetics, and
transplantation outcome, including regimen-related toxicity. One hundred eighty-one patients were
randomized and 179 patients were eligible for analysis. Overall, CR rates were 81.9% for the aprepitant and
65.8% for the placebo arms (P < .001). Percentages of patients with no emesis all days were 73.3% for
aprepitant and 22.5% placebo (P < .001). Mean VAS scores were 16.6 mm aprepitant and 16.9 mm placebo
(NS), and there were no differences in the amount of rescue antiemetics used, regimen related toxicity,
engraftment, or transplantation outcome. Aprepitant in combination with dexamethasone and ondansetron
signiﬁcantly decreased emesis and signiﬁcant nausea, whereas not increasing RRT or affecting short-term
survival but had no signiﬁcant impact on the use of PRN antiemetics, or overall VAS nausea scores.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Prevention of nausea and vomiting remains a challenge
for patients receiving highly emetogenic preparative regi-
mens before stem cell transplant despite the use of 5-HT3
antagonists [1]. The 5-HT3 antagonists are effective in pre-
venting acute nausea and vomiting in this patient group;
however, control decreases rapidly over the days of the
preparative regimen from 90% on day 1 to 10% by the end of
the preparative regimen [2]. This is likely because serotonin
release is not a major etiologic factor in the delayed phase of
chemotherapy-induced nausea [3].
Aprepitant is a neurokinin-1 antagonist that interferes
with the effects of the neuropeptide, substance P [4]. In
animal studies, neurokinin-1 antagonists are effective in
controlling emesis induced by emetogenic stimuli against
which 5-HT3 antagonists have little effect, including
apomorphine, loperamide, copper sulfate, and motion-
induced emesis [4,5]. It is Food & Drug Administration (FDA)-iety of Hematology Annual Meeting,
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12.07.019approved and administered for 3 days to patients receiving
highly and moderately emetogenic chemotherapy, where its
major impact is in preventing delayed nausea and vomiting
in naively treated patients [6-10]. The etiology of nausea and
vomiting in the stem cell transplant population is multifac-
torial and includes anticipatory effects in these typically
heavily treated patients, side effects of prophylactic antibi-
otics and narcotic analgesics, and the high-dose preparative
regimens that lead to a poor end-of-regimen control rate,
making aprepitant an attractive addition to standard anti-
emetic regimens for these patients.
However, as transplantation preparative regimens typi-
cally take up to a week to administer, it is important to
provide effective drug levels throughout the preparative
regimen and 3 days beyond or signiﬁcantly longer than the
drug is currently used, which could have toxicity implica-
tions. When used only 3 days as approved by the FDA,
aprepitant is a substrate for and moderate inhibitor of
CYP3A4 and a mild inducer of CYP2C9. However, when used
for more than 7 days, aprepitant may actually act as an
inducer of CYP3A4 [11,12]. As both etoposide and high-dose
cyclophosphamide are metabolized by CYP3A4, so aprepi-
tant could theoretically affect the transplantation outcome as
well as regimen-related toxicity (RRT) in this setting.
Therefore, we conducted a prospective, randomized,
double-blind phase III trial of aprepitant for the prevention ofTransplantation.
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preparative regimens before stem cell transplant (SCT), in
which the aprepitant was given daily during and for 3 days
after the preparative regimen ﬁnished with endpoints of
both efﬁcacy and toxicity as measured by engraftment, RRT,
and progression-free survival (PFS) and overall survival (OS)
[13]. As such, the trial required an investigational new drug
number due to its non-FDA-approved dosing and was
registered at ClinicalTrials.gov Identiﬁer NCT00781768.
PATIENTS AND METHODS
Design
This study was a single-center, comparative, randomized, double-blind,
phase III trial designed to evaluate the efﬁcacy of oral aprepitant (Emend;
Merck & Co., West Point, PA) in combination with ondansetron and dexa-
methasone in the prevention of acute and delayed nausea and vomiting
compared to ondansetron and dexamethasone alone in patients receiving
highly emetogenic preparative regimens before autologous or allogeneic
SCT. The protocol was approved by the institutional review board, and
written informed consent was obtained from each patient.
Patients
Eligible patients were at least 18 years of age, had malignant disease,
consumed <5 alcoholic drinks per day in the past 1 year, and were sched-
uled to receive 1 of 5 myeloablative high-dose cyclophosphamide prepar-
ative regimens before SCT: total body irradiation (TBI)/etoposide/
cyclophosphamide (Cy) [14] (TBI 1200 Gy fractionated into 8 doses on days
-8, -7, -6, and -5, etoposide 60 mg/kg i.v. over 4 hours on day -4, Cy 100 mg/
kg i.v. over 2 hours on day -2), busulfan (Bu)/Cy [15,16] (oral Bu 0.875mg/kg/
dose or i.v. Bu 0.8 mg/kg/dose every 6 hours  16 doses given on days -7, -6,
-5, -4 and Cy 60 mg/kg i.v. over 1 hour on days -3 and -2), etoposide,
cytarabine, melphalan/VP/Cy [17] (carmustine 15 mg/kg i.v. over 2 hours on
day -6, etoposide 60 mg/kg i.v. over 4 hours on day -4, Cy 100 mg/kg i.v. over
2 hours on day -2), and TBI/Cy [18] (TBI¼ 1200 cGy fractionated into 8 doses
on days -7, -6, -5, and -4, and Cy 60 mg/kg i.v. over 1 hour on days -3 and -2).
Patients were required to have an estimated creatinine clearance of at least
50 mL/minute and normal liver function, deﬁned as a total bilirubin less
than 1.5  upper limit of normal and an aspartate aminotransferase <2 
upper limit of normal.
Procedures
Patients who met the eligibility criteria were stratiﬁed by gender [13]
and randomized to 1 of 2 treatments: dexamethasone 7.5 mg i.v. once daily
and ondansetron 8 mg orally every 8 hours on each day of the preparative
regimen plus 1 additional day combined with aprepitant; 125 mg orally on
the ﬁrst day of their preparative regimen followed by 80 mg daily on each
remaining day of the preparative regimen plus 3 additional days; or dexa-
methasone 10 mg i.v. once daily and ondansetron 8 mg orally every 8 hours
on each day of the preparative regimen plus 1 additional day plus aprepitant
placebo. As noted above, the dose of blinded dexamethasone varied because
of a known drug interaction between it and aprepitant. Lorazepamwas used
for breakthrough nausea or vomiting andwas allowed as needed for anxiety,
catheter insertion, and sleep. Phenytoin [1 g loading dose day 1, then 400mg
daily (days -7 to -2] was used as seizure prophylaxis in patients receiving i.v.
Bu/Cy. Prochlorperazine was allowed only for repeated episodes of vomiting
(deﬁned as >4 episodes in any 12-hour period).
Assessments
Episodes of vomiting as well as any rescue antiemetics were recorded.
Retching was counted as an emetic episode. For the purpose of determining
risk factor balance in all arms, patients were asked to ﬁll out a questionnaire
pertaining to their history of nausea and vomiting associated with prior
chemotherapy, radiation, or pregnancy as well as history of motion sickness
or anticipatory nausea and vomiting. Self-grading of nausea was performed
daily using a visual analog scale (VAS), a 100-mm line marked no nausea at
one end (0 mm) and severe nausea at the other end (100 mm).
Evaluation of Response
The primary efﬁcacy endpoint was to determine and compare the rate of
complete response (CR; deﬁned as no emesis with only grade 1-2 nausea:
patient able to eat; reasonable intake, using National Cancer Institute
Common Toxicity Criteria 3.0) during and 3 days after high-dose therapy in
patients treated with aprepitant in addition to oral ondansetron and i.v.
dexamethasone compared to the standard regimen of oral ondansetron and
i.v. dexamethasone in the stem cell transplant setting. The secondary efﬁ-
cacy endpoints were to compare the degree of nausea, as measured usingthe VAS, and total number of antiemetic breakthrough doses administered
in each arm of the study.
Overall nausea was analyzed by averaging daily VAS scores in each arm
of the study. Major and minor responses and failure rates were also deter-
mined. Major response (MR) was deﬁned as 1 episode of vomiting or if no
vomiting occurred, moderate nausea (intake signiﬁcantly decreased but
patient can eat) with rescue antiemetics allowed. Minor response (mR) was
deﬁned as 2 to 4 episodes of vomiting regardless of nausea or rescue anti-
emetic use. Failure (F) was deﬁned as >4 episodes of vomiting regardless of
nausea or rescue antiemetic use. Major efﬁcacy (ME) was deﬁned as
complete responders plus major responders. Daily responses were averaged
and results are reported as composite scores.
The primary toxicity endpoint was to determine RRT and 1-year survival
rate. RRT was measured by documenting engraftment and all non-
myelosuppressive grade III or IV toxicity during and after the ﬁrst 30 days
after the completion of the last dose of aprepitant. WBC engraftment was
deﬁned as the ﬁrst day the absolute neutrophil count reached 500/mL sus-
tained for 3 consecutive days, and platelet engraftment was deﬁned as the
ﬁrst of 7 days the platelet count reached 20,000/mL without transfusion.
The deﬁnition of CR allowed the use of lorazepam because its use in this
patient population was universal for various indications, including anxiety
and insomnia; however, an additional analysis was done to determine the
percentage of patients with no emesis, less than grade 3 nausea, and no
rescue (PRN) medications over the entire 8- to 10-day treatment period.Statistical Methods
The study design was a stratiﬁed 2-sample binomial proportions
controlled trial. Based on our earlier hematopoietic stem cell transplant
antiemetic study [2], it was estimated that, for the control arm, the absence
of emesis during the preparative regimens would be approximately 30%. By
modeling based on aprepitant studies in highly emetogenic standard dose
chemotherapy, we determined that a complete control rate of 50% would be
expected. Based on this, the estimated sample size was 90 patients per arm,
which would provide 80% power to detect a difference of 20% between the
null hypothesis that both groups have a 30% delayed emesis rate and the
alternative hypothesis that the no emesis rate in the experimental group is
50% with a signiﬁcance level (alpha) of 0.05, using a 2-sided 2-sample t test
based on the normal approximation to the binomial distribution.
All study variables are summarized using descriptive statistics. Inde-
pendent t tests were used for continuous, normally distributed data to
compare the 2 groups. For data that was not normally distributed, the
nonparametric Pearson Chi-Square and the Mann-Whitney U statistics
were used to determine associations between the 2 groups. All nominal
data using the 1-year OS and 1-year PFS were calculated using the Kaplan-
Meier method, and the difference in survival rate was determined by the
log-rank test.
Statistical analyses were performed using SPSS for Windows (SPSS, Inc.,
Chicago, IL) with signiﬁcance determined at a 2-sided level of <.05.
RESULTS
Patients
A total of 264 eligible patients were seen during the
registration period between September 2004 and July 2008
(Consort Diagram; Table 1). Of these, 181 were randomized
into the study. The majority of those not enrolling declined,
citing concerns of increased RRT or the potentially dimin-
ished efﬁcacy of the transplantation. Two randomized
patients never proceeded to transplantation and did not
receive the study drug. They are not included in the analysis.
Ten patients withdrew consent during the trial (6 in the
aprepitant arm and 4 in the placebo arm). Four patients
withdrew due to side effects: 1 patient in the placebo arm
quit due to a panic attack; 3 patients withdrew in the apre-
pitant arm due to seizures with visual hallucinations, dizzi-
ness, and anxiety, respectively. The remaining 6 patients (3 in
each arm) quit due to poor nausea and/or emesis control.
Treatment groups were stratiﬁed based on gender and
were balanced with respect to age, weight, and history of
nausea and vomiting with prior chemotherapy (Table 2).
Results of the questionnaire pertaining to history of nausea
and vomiting are reported in Supplementary Table S1.
All patients who received the study drug were included in
the intent-to-treat analysis. Overall, 1597 of 1644 (97%) VAS
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breakthrough antiemetic in this trial. Additional break-
through antiemetics were to be administered only if patients
failed lorazepam, which we deﬁned as deﬁned as >4
episodes in any 12-hour period, but were used in 52 of 179
patients (29%), usually because of signiﬁcant but lesser
amounts of nausea after lorazepam, often requested by
patient/family members.
Efﬁcacy
For the primary and secondary endpoints, the data was
analyzed as composite responses (average daily responses)
to account for the different lengths of the preparative regi-
mens, which ranged from 5 to 8 days. Patients who received
aprepitant had signiﬁcantly higher CR rates (81.9% versus
65.8%; P < .001) compared to the standard ondansetron plusTable 1
Consort Diagram
Assessed for eligib
Analyzed (n = 90)  
Excluded from analysis (n = 2). Not 
transplanted; did not receive study drug 
Discontinued intervention (n = 6) 
Adverse event (n = 3) 
Poor control of nausea/vomiting (n = 3)
Allocated to intervention (n = 92) 
Received allocated intervention (n = 90)
Did not receive allocated intervention (did 
not receive study drug) (n = 2)
Randomized (n
Aprepitant 125 mg po d1, then 80 mg daily 
  during preparative regimen + 3 days 
Dexamethasone 7.5 mg IV daily during  
  preparative regimen + 1 day 
Ondansetron 8 mg po q8h daily during 
preparative regimen + 1 daydexamethasone treatment. Composite MR and ME rates
were also signiﬁcantly higher in the aprepitant arm, while
mR and F rates were signiﬁcantly higher in the control arm
(Table 3).
Emesis was controlled to a much greater degree than
nausea. Patients receiving aprepitant experienced signiﬁ-
cantly better complete control of vomiting (73.3% versus
22.5%; P ¼ .001) compared to standard therapy. The cumu-
lative percentage of patients with emesis is shown in
Figure 1. Fewer total rescue doses were given in the aprepi-
tant arm than in the control arm (594 versus 852; P ¼ .033).
This is equivalent to an average of 6.6 breakthrough doses
per patient in the aprepitant armversus 9.6 doses per patient
in the placebo arm. This difference, however, was not re-
ﬂected in the subjective measure of nausea; the VAS scores
(0-100; with 100 ¼worst imaginable nausea) were 16.5 mmility (n = 264) 
Excluded (n = 84) 
Not meeting inclusion criteria (n = 7) 
Declined to participate (n = 75) 
Other reasons (n = 2) 
Discontinued intervention (n = 4) 
Adverse event (n = 1) 
Poor control of nausea/vomiting (n = 3)
Allocated control regimen (n = 89) 
Received allocated intervention (n = 89)
Analyzed (n = 89) 
 = 181) 
Placebo po daily  
  during the preparative regimen + 3 days 
Dexamethasone 10 mg IV daily during the 
  preparative regimen + 1 day 
Ondansetron 8 mg po q8h daily during 
  preparative regimen + 1 day 
Table 2
Patient Characteristics
Placebo
N ¼ 89
Aprepitant
N ¼ 90
P
Value
Test
Age in years (median) 51 (19-79) 50 (20-75) .124 t test
Weight in kg (median) 82 (59-139) 83 (48-187) .14 t test
Gender
Male 57 57
Female 32 33 .921 Chi-square
Diagnosis
Non-Hodgkin
lymphoma
28 29
AML 22 24
Multiple myeloma 21 13
ALL 3 10
Hodgkin’s lymphoma 7 5
CML 4 2
Other* 4 7
Setting
Inpatient 69 74
Outpatient 20 16 .433 Chi-square
Graft type
Auto-PBPCT 48 (53%) 41 (44%)
Related allo-PBPCT 19 22
Related allo-BMT 1 1
MUD PBPCT 8 12
MUD BMT 6 8
CORD 7 6 .862 Chi-square
Preparative regimen
TBI/Cy 33 46
i.v. Bu/Cy 7 7
Prescribed orally
Bu/Cy
21 13
TBI/VP/Cy 17 19
BCV 11 5 .173 Chi-square
History of prior nausea and vomiting with chemotherapy
Yes 55 59
No 30 25 .443 Chi-square
History of prior nausea and vomiting with radiation therapy
Yes 42 41
No 43 42
N/A 0 3 .221 Chi-square
AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myelogenous leukemia; Auto-PBPCT, autologous-peripheral
blood stem cell transplant; allo, allogeneic; BMT, bone marrow transplant;
MUD, matched unrelated donor; CORD, cord as in umbilical cord; TBI, total
body irradiation; Cy, cyclophosphamide; Bu, busulfan; VP, etoposide
(VP16); BCV, (BCNU, cyclophosphamide, VP16); N/A, not applicable.
* Other diagnoses included myelodysplastic syndrome (MDS), myelo-
proliferative disorder (MPD), chronic lymphocytic leukemia (CLL),
myeloﬁbrosis.
Table 3
Efﬁcacy and Survival
Placebo
N ¼ 89
Aprepitant
N ¼ 90
P
Value
Primary endpoints
CR % composite (all days) 65.8 81.9 <.001
PFS (months) 28.57 28.33 .727
OS (months) Not reached 44.4 .5446
Secondary endpoints
Acute CR % (day 1) 87.6 96.7 .028
No emesis all days % 22.5 73.3 <.001
Average nausea score (VAS) (mm) 16.9 16.5 .892
MR % composite 21.6 16.0 .011
mR % composite 10.3 2.0 <.001
F % composite 2.2 0.1 .001
ME ¼ CR þ MR 87.4 97.9 <.001
Time to ﬁrst emesis-days (mean) 4.5 5.8 .028
Number of PRN doses used 852 594 .033
Additional analyses
% of patients with no emesis
<grade 3 nausea All days-PRNs
allowed
14.6 48.9 <.001
% of pts with no emesis
<grade 3 nausea All days-No
PRNS
11.2 11.1 .979
CR, complete response; PFS, progression-free survival; OS, overall survival;
VAS, visual analog scale; MR, major response; mR, minor response; ME,
major efﬁcacy; F, failure.
CR ¼ % of days with no emesis, <grade 3 nausea.
Average Nausea Scores (mm) (VAS 0 ¼ no nausea, 100 ¼ worst possible).
MR ¼ % of days with 1 episode of emesis, <grade 4 nausea.
mR ¼ % of days with 2 to 4 episodes of emesis, regardless of nausea.
F ¼ % of days with >4 episodes of emesis.
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arm, respectively.
As conventional dose chemotherapy antiemetic trials
typically report response rates over the entire treatment
period, we did these analyses as well. Over the entire treat-
ment period, 48.9% of patients on the aprepitant arm were
able to maintain a reasonable intake of food (>50% of normal
as recorded by staff nurses) versus only 14.6% of patients in
the placebo arm. The vast majority of patients in both arms
used lorazepam therapy during the trial (88.9% versus 88.8%;
P ¼ .979 aprepitant versus control). These percentages
represent doses charted as “given for nausea” or presumed
nausea when no indication was charted, not doses given
before catheter insertion for continuous bladder irrigation or
doses charted as given for anxiety or sleep.
Safety
Five patients died in the aprepitant arm due to sepsis (3
patients), toxic epidermal necrolysis and sepsis (1 patient),
and veno-occlusive disease of the liver (1 patient), whereas 2
patients died in the control arm due to viral pneumonia/encephalitis (1 patient) and fungal pneumonia (1 patient)
within 30 days. All but 1 patient in each group had under-
gone allogeneic transplants. Noninfectious grade III or IV
toxicity (excluding myelosuppression and grade III mucosi-
tis) within 30 days of receiving the study drug occurred in 5
patients (Table 4): 3 patients in the aprepitant arm (1 each of
a right hemispheric stroke attributed to antilymphocyte
globulin, alveolar hemorrhage, and grade IV mucositis
requiring intubation) and 2 in the control arm (seizure
attributed to busulfan and a presumed pre-existing myelo-
dysplastic syndrome diagnosed day þ28). Other nonsigniﬁ-
cant differences were heartburn, which was seen in the
aprepitant group in 12 of 90 patients versus 6 of 89 patients
in the controls, and asthenia in 6 of 90 patients versus 1 of 89
patients (Table 3).
Aprepitant did not have a negative effect on engraftment.
Median time to WBC engraftment was 11 days aprepitant
versus 10 days placebo (P ¼ .778), whereas time to platelet
engraftment was 11 days in both arms (P ¼ .8206). Patients
in the aprepitant group had a nonsigniﬁcant higher (6%)
tacrolimus level on the day of transplantation (P ¼ .5858),
which was not enough to recommend an adjustment of our
standard starting dose of 0.03mg/kg continuous i.v. on day2.
PFS measured 1 year after transplantation showed no
signiﬁcant difference as shown in Figure 2. Similarly there
were no differences in 1 year OS, and the median was not
reached. A subset analysis of the 51 patients who received
high-dose etoposide as part of their regimen was not pow-
ered for signiﬁcance, but also showed no difference in RRT or
outcome.DISCUSSION
Currently, both the Multinational Association of
Supportive Care in Cancer and the American Society of
Clinical Oncology recommend only a 5-HT3 antagonist with
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Figure 1. Cumulative percentage of patients with emesis by day.
Table 4
Grade III/IV Adverse Reactions
Placebo N ¼ 89 Aprepitant N ¼ 90
Diarrhea 52 59
Headache 46 44
Fatigue 34 37
Constipation 21 28
Fever 19 22
Hiccups 20 21
Heartburn 6 12
Lightheadedness/dizziness 5 7
Engraftment failure 3 (all PLT only) 5 (3 PLT only)
Weakness 1 6
Pruritus 2 2
Restlessness 0 3
Vasovagal episode 3 0
Hallucinations (1 with seizure*) 0 2
Ileus 0 2
Bloody emesis 2 0
Orthostatic hypotension 1 1
Delayed engraftment 1 0
* Seizure attributed to busulfan.
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therapy [19,20]. This study was conducted to ascertain
whether aprepitant decreased the incidence of nausea and
vomiting associated with highly emetogenic preparative
regimens without negatively affecting patient outcome. We
found CR rates (no vomiting, no or mild nausea with break-
through antiemetics allowed) to be 81.9% of patients
receiving aprepitant versus 65.8% placebo (P < .001).
Complete protection from emesis for the entire 8 to 10 days
of treatment was achieved in 73.3% of patients in the apre-
pitant arm versus only 22.5% of patients in the placebo arm,
suggesting that this agent be incorporated into the standard
antiemetic regimen for patients who undergo bone marrow
transplants.
Similar to standard dose chemotherapy regimens, apre-
pitant had a much higher impact on emesis than it did on
nausea as it neither abrogated the need for rescue medica-
tions nor changed the patients’ perceptions of nausea as VAS
scores were identical between the 2 groups. It did, however,
improve thepercentageofpatientswhowere able tomaintain
a reasonable intake of food over the entire treatment period
(48.9% versus 14.6% aprepitant versus placebo; P < .001).
The ondansetron doses used in this trial were carried over
from a previous trial, which found 8mg of ondansetron every
8 hours as effective as 32 mg i.v. daily. The dexamethasone
dose of 10 mg given i.v. daily in the placebo group was
dose-reduced 25% (to 7.5 mg) in the aprepitant arm based
on the known i.v. methylprednisoloneeaprepitant interac-
tion information availablewhen the trialwasdesigned,which
showed a similar dexamethasone pharmakinetic proﬁle for
patients receiving the identical dose of aprepitant [10].
There are few prospective antiemetic studies using apre-
pitant in the transplantation settingagainstwhich tocompare
this trial. A small (N ¼ 30) pilot trial by Bubalo et al. [21]
reported an overall response rate (CR þ MR) of 93% versus
33% for aprepitant versus placebo (P ¼ .014) and no emesis
in 66.7% versus 33% aprepitant versus placebo (P¼ .143). This
study also allowed rescue medications as part of their CR
criteria. An open-label noncomparative exploratory trial of 42
patients by Paul et al. [22] found an average 54% completeemetic response rate, which was signiﬁcantly lower than the
73.3% rate found in our study. Patients in this trial received
only 3 days of aprepitant, which is possibly the reason for the
lower response rates.
Safety was another important endpoint of this study,
given that prolonged administration of aprepitant in the
presence of high-dose chemotherapy regimens had the
potential of increasing toxic deaths or diminishing the efﬁ-
cacy of the preparative regimens. Cyclophosphamide is an
inactive prodrug that is converted to the cytotoxicmetabolite
4-hydroxycyclophosphamide by the cytochrome P450
isoenzymes CYP2B6, CYP2C9, and CYP3A4/5 in the liver. This
bioactivation is potentially saturable at high doses [23] and
could theoretically be negatively affected by aprepitant,
which is a moderate inhibitor of CYP3A4 plus a mild inducer
of CYP2C9 when used for 3 days, and possibly an inducer of
CYP3A4 when used more than 7 days [6]. These changes
were not found in aprepitant-treated patients in the clinical
Figure 2. Progression-free survival in all 179 patients (P ¼ .727).
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metabolites. Considering this and the lack of a difference in
1-year PFS or OS for patients receiving aprepitant versus
placebo, we conclude that aprepitant can safely be used with
high-dose cyclophosphamide.
We also considered other drug interactions as being
potentially signiﬁcant in this trial. Our study did not have
enough patients receiving etoposide to reach a deﬁnitive
conclusion regarding the safety of aprepitant with high-dose
etoposide, which is another agent metabolized by CYP3A4;
pharmakinetic studies are recommended. All patients
receiving i.v. busulfan also received phenytoin, a strong
inducer of CYP3A4 known to decrease aprepitant levels. This
interactionseemedtobeclinically insigniﬁcantasnoneof the7
patients receiving this agent experienced any vomiting during
phenytoin treatment. Phenytoin was added in this group per
the package insert because in dose-ﬁnding studies for i.v.
busulfan, phenytoin was shown to potentially affect busulfan
levels, which at the time of this study were not measured. Of
note, only 1 patient on the study died of veno-occlusive
disease; however, this patient received the TBI/Cy regimen.
We found that aprepitant was well tolerated; only
heartburn and asthenia were more commonly reported in
the study versus the control arm. Seven patients (3.9%) died
of infection within 30 days of receiving the study medica-
tion: 5 in the aprepitant arm and 2 in the placebo arm. It is
possible that the prolonged use of dexamethasone up to 9
days as part of the antiemetic regimen used in this study
could have, therefore, impacted the infection risks, particu-
larly in the 51.4% of patients undergoing allogeneic trans-
plantation, but this infection risk was no higher than our
initial study [2] without aprepitant and we would have ex-
pected no imbalance in the 2 arms.
Multiday high-dose preparative regimens are the ulti-
mate challenge of any antiemetic regimen. We found that up
to 9 days of aprepitant in combinationwith ondansetron and
dexamethasone signiﬁcantly decreased the incidence of
emesis in this trial, which led to an increase in oralalimentation. However, further research is needed to
completely control nausea in this setting. Of note, a recent
comparative trial found daily palonosetron to be superior to
daily ondansetron in acute myelogenous leukemia in pre-
venting delayed nausea [25]. This suggests that further study
of daily aprepitant with palonosetron versus ondansetron in
patients receiving multiday high-dose therapy in the trans-
plant may prove even more beneﬁcial than the current novel
regimen in eliminating the severe nausea seen in these
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Questionnaire Results: History of Nausea and Vomiting
Placebo*
N ¼ 89
Aprepitant*
N ¼ 90
P Value
Hx of prior nausea and vomiting with chemotherapy
Yes 55 59
No 30 25
Missing response 4 6 .443
Hx of prior nausea and vomiting with chemotherapy
Mild 30 30
Moderate 11 17
Severe 14 11
N/A 30 25 .614
Missing response 4 7
Hx of prior nausea and vomiting with RT
Yes 42 41
No 43y 42y
Missing response 4 7 .221
Hx of prior nausea and vomiting with RT
Infrequent 25 25
Moderate 8 7
Severe 12 9
N/A 40y 44y
Missing response 4 5 .877
Hx of motion sickness
No 72 63
Yes 13 22
Missing response 4 5 .088
Hx of morning sickness
N/A 61 61
No 9 10
Mild 8 8
Moderate 3 5
Severe 4 2
Very severe/hospitalized 1 0
Missing response 3 4 .818
Hx indicates history; RT, radiation therapy.
* Entire questionnaire was missing for 3 patients in the placebo arm and 4 patients in the aprepitant arm. Some patients did not answer all questions, likely
due to only prior treatment, a tyrosine kinase inhibitor, or no prior treatment. One patient put a question mark near the question of motion sickness.
y The “no” response to question 3 should logically equate to the “N/A” response in question 4, but it did not; patients may have misread the question.
